Conexeu PreHealth

Chapter 04 · Competitor showcase · read 2026-08-20

Conexeu has three sets of competitors and they are losing on three different axes.

The companies whose products compete with CXU™ are barely on social. The companies who own the aesthetics conversation are on the wrong axis. The companies who own the regeneration narrative are individuals, not brands.

  • Ring 1: 6 structural analogs
  • Ring 2: 5 category owners
  • Ring 3: narrative peers
  • 0 brand TikToks — deliberately

Three rings

Who Conexeu is actually competing with, and for what

Treating “competitor” as one list is why most competitive social audits produce nothing usable. These three rings compete for different things and are beaten in different ways.

Ring 1 · Structural analogs

MTF Biologics (Renuva), Aroa Biosurgery, Organogenesis, MiMedx, Integra LifeSciences, Tela Bio. They compete for the same clinical job — giving host cells a structure to populate. They are almost absent from consumer social.

Ring 2 · Category owners

Allergan Aesthetics, Galderma, Merz, Evolus, Prollenium. They do not compete for the job; they compete for the same attention and the same injector relationships. They own the feed and they own it with results content.

Ring 3 · Narrative peers

CollPlant, CELLINK/BICO, Establishment Labs, and the individual scientists at WFIRM, the Wyss Institute and adMare. They compete for the future story — who gets believed about what regeneration will be.

RingCompetitorWhere they are strongWhere they are open
1Renuva / MTF BiologicsThe only Ring-1 player with a real consumer presence: 13,600 IG followers, an active reel cadence, a recognisable Q&A format, and an “elite injector” scarcity frame. Follows 4,528 accounts — deliberate reciprocal growth.Everything runs through practitioner and patient results. No mechanism animation. No brand TikTok. Its own hashtag is unusable.
1Aroa BiosurgeryClosest structural analog to CXU™. Clinical-publication discipline; a separate showcase page for the ECM platform itself.4,565 followers and 32 engagements on its best recent post. Text-and-link cadence with no visual mechanism asset at all.
1MiMedx236 engagements on a distribution-agreement post — the strongest absolute number in Ring 1. Real commercial news flow.Corporate-announcement register throughout. No mechanism content, no named scientists, no consumer surface.
1Integra LifeSciences100,252 LinkedIn followers. The incumbent in dermal regeneration; conference and product-launch machine.Surgical audience only. Nothing in aesthetics, nothing consumer-facing, nothing that explains the technology to a non-specialist.
2Allergan Aesthetics150,000 IG followers. Partner-creator content most weeks, provider-privileges programme, an owned quiz format (“What’s your Aesthetics ID?”).Entirely results and lifestyle. Its own 2026 data says 81% of providers reach for HA on GLP-1 patients — and it has no answer for the structural question that raises.
2Galderma (Sculptra, Restylane)Holds the category ceiling post at 56.8 per thousand, plus 558,848 LinkedIn followers and a chair who posts in the first person. Owns “regenerative biostimulator” as a phrase.“Regenerative” is doing enormous work for a collagen-stimulation mechanism. That is a definitional gap a scaffold company can open.
2Merz Aesthetics (Radiesse, Xeomin)40,900 IG followers, a data-led register (“new data, new insights”), and named KOLs on camera.6× internal spread between its science content and its trade content, and it keeps publishing the trade content. Carries an FDA reprimand history on Instagram promotion.
2Evolus / Prollenium59,000 and 31,000 IG followers respectively, on consumer-lifestyle tone.Revanesse’s lifestyle POV format earns 2.2 per thousand. Large audience, very thin engagement — reach without belief.
3CollPlantThe most direct narrative competitor to B.R.E.A.S.T.™: 3D-bioprinted regenerative breast implants from recombinant human collagen, with a CELLINK manufacturing partnership and preclinical studies running.Investor-conference register only. The technology is spectacular and almost none of it has been made visual for a non-specialist audience.
3Individual scientistsThis is where Ring 3 is actually won. A Wyss researcher introducing a vascularised-tissue programme pulled 190 engagements on video with no brand behind her.No company in any ring is systematically converting its own scientists into channels. Conexeu has two founder-scientists and a CMO.

Follower counts and engagement figures read off the live pages on 2026-08-20. “Where they are open” is our read, not the competitor’s.

Their best work

The best post from each ring, and what it concedes

Instagram

Ring 2 — Galderma

Best in category · animated cross-section

Sculptra works across all 3 layers of the skin — epidermis, dermis and hypodermis.

Engagements
4,337
Per 1k
56.8
Ring
2

Why it worked

The category’s best post is a diagram. Galderma proved the appetite exists and then went back to results content.

It also over-reaches: “regenerative biostimulator” is a collagen-stimulation mechanism wearing a regeneration word. The film is doing definitional work the product cannot fully support.

Conexeu’s version

The concession is enormous: they have demonstrated that this audience will watch a mechanism film to the end, and they have left the actual architecture story unclaimed. Conexeu’s product is the structure Galderma’s copy is borrowing the language of.

See the post
LinkedIn

Ring 1 — Aroa Biosurgery

Nearest structural analog · text and link

Minimal complications. Maximum confidence. Across multiple clinical publications Myriad has consistently demonstrated…

Reactions
31
Followers
4,565
Per 1k
7.0

Why it worked

This is the closest company in the world to Conexeu’s technical positioning, with real clinical publications behind it, and its best recent post is three bullets and a link at 32 engagements.

The ECM platform has its own showcase page — 1,315 followers — which is the right structural instinct with nothing built on top of it.

Conexeu’s version

Ring 1 is not defending anything. A single well-made mechanism film would make Conexeu the most visible ECM-scaffold company on consumer social inside a quarter, and Aroa’s numbers are the proof that nobody would contest it.

See the post
LinkedIn

Ring 3 — Wyss Institute researcher

Narrative peer · personal video

I’m thrilled to introduce ReConstruct: vascularized tissues for breast reconstruction.

Reactions
163
Comments
27
Budget
None

Why it worked

27 comments is the number to notice. Personal scientific announcements generate conversation at a rate no brand page achieves, and comment depth is what LinkedIn distribution actually keys on.

The subject is directly adjacent to B.R.E.A.S.T.™ — bioprinted vascularised tissue for breast reconstruction — and the post was made by an individual, from an institute, with no company behind it.

Conexeu’s version

Conexeu is running a preclinical programme at the Wake Forest Institute for Regenerative Medicine and announced it as a text-and-link post that earned 30. The same news, told in the first person by the CSO, is the strongest LinkedIn asset the company has and it has never been used that way.

See the post

No company in any of the three rings has a brand TikTok account — and the interesting question is not why Conexeu is missing, but why companies with far larger budgets decided the same thing.

We searched for official brand accounts for the two most relevant products in the category and found none. The treatment conversation on TikTok is carried entirely by practitioners, med spas and patients — parties who are regulated as practitioners, not as manufacturers, and who therefore carry a different and much lighter promotional burden.

That asymmetry is the whole explanation. An injector can post a result; the company whose product produced it usually cannot. So the absence reads as a shared regulatory judgment rather than an unclaimed lane, and Chapter 06 sets out the four mechanisms behind it.

The audience fact still stands, and it still matters: TikTok, Instagram and review sites drive most aesthetic patient decisions, and 63% of GLP-1 patients seeking facial treatment had never used cosmetic medicine before. That demand is real. The open question is which surface Conexeu can lawfully meet it on — and today the answer is Reels, not TikTok.